Celgene Signs an Exclusive WW License Option with Obsidian for DDs Technology

 Celgene Signs an Exclusive WW License Option with Obsidian for DDs Technology

Celgene Signs an Exclusive WW License Option with Obsidian for DDs Technology

Shots:

  • Celgene to utilize Obsidian’s DDs (Destabilizing Domains) technology for its cell therapy candidates with DD-regulated IL12 or CD40L proteins for oncology indications
  • Obsidian will receive an undisclosed upfront in cash and equity and is eligible to receive an undisclosed milestone, plus royalties
  • Obsidian’s is developing DDstechnology to regulate expression of immunomodulatory factors, for precise pharmacologic control of the potent acitivity with optimized safety and efficacy in engineered cell therapies

Click here to read full press release/ article | Ref: Obsidian | Image: Atlas venture

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post